MedPath

Sertraline

Generic Name
Sertraline
Brand Names
Zoloft
Drug Type
Small Molecule
Chemical Formula
C17H17Cl2N
CAS Number
79617-96-2
Unique Ingredient Identifier
QUC7NX6WMB
Background

Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as Citalopram and Fluoxetine. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects.

Several weeks of therapy with sertraline may be required before beneficial effects are noticed. Sertraline displays enhanced safety or tolerability than other classes of antidepressants, which frequently cause high levels of drowsiness, dizziness, blurred vision, and other undesirable effects.

Indication

Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD). Common off-label uses for sertraline include the prevention of post stroke depression, generalized anxiety disorder (GAD), fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neurocardiogenic syncope.

Associated Conditions
Binge Eating Disorder (BED), Bulimia Nervosa, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD)
Clinical Trials
Related News

A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder (PTSD)

Phase 2
Completed
Conditions
Stress Disorders, Post-Traumatic
Interventions
First Posted Date
2017-01-26
Last Posted Date
2021-12-08
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
336
Registration Number
NCT03033069
Locations
🇺🇸

Investigational Site, Everett, Washington, United States

Cryptococcal Antigen Screening Plus Sertraline

Phase 3
Terminated
Conditions
Cryptococcosis
Cryptococcal Infections
AIDS-Related Opportunistic Infections
Interventions
Drug: Placebo Oral Tablet
First Posted Date
2016-12-23
Last Posted Date
2020-06-09
Lead Sponsor
University of Minnesota
Target Recruit Count
22
Registration Number
NCT03002012
Locations
🇺🇬

Infectious Disease Institute, Makerere University, Kampala, Uganda

CAMH - McMaster Collaborative Care Initiative For Mental Health Risk Factors In Dementia

Not Applicable
Completed
Conditions
Depression
Mild Cognitive Impairment
Anxiety
Interventions
Other: CBT/Psychological Therapy
Other: Psychiatric Consultation
Other: Lifestyle Intervention Resources
First Posted Date
2016-11-04
Last Posted Date
2021-01-07
Lead Sponsor
Centre for Addiction and Mental Health
Target Recruit Count
145
Registration Number
NCT02955719
Locations
🇨🇦

Centre for Addiction and Mental Health, Toronto, Ontario, Canada

The Therapeutic Effect of Transcranial Direct Current Stimulation on Depression in Parkinson's Disease

Phase 1
Terminated
Conditions
Parkinson Disease
Depression
Interventions
Device: active tDCS
Device: sham tDCS
First Posted Date
2016-09-28
Last Posted Date
2021-10-20
Lead Sponsor
National Cheng-Kung University Hospital
Target Recruit Count
15
Registration Number
NCT02917122

Cost- Effectiveness and Quality of Life Assessment in Bipolar Disorder Depressive Episode

Phase 4
Completed
Conditions
Bipolar Disorder
Interventions
First Posted Date
2016-09-28
Last Posted Date
2020-11-20
Lead Sponsor
Federal University of Rio Grande do Sul
Target Recruit Count
78
Registration Number
NCT02918097

Sertraline in Addition to Standard of Care Treatment for Coccidioidomycosis

Phase 2
Withdrawn
Conditions
Coccidioidomycosis
Interventions
First Posted Date
2016-09-20
Last Posted Date
2022-03-21
Lead Sponsor
University of California, San Francisco
Registration Number
NCT02908334

Cost- Effectiveness and Quality of Life Assessment in Major Depression Disorder

Phase 4
Completed
Conditions
Depression
Interventions
First Posted Date
2016-09-15
Last Posted Date
2020-10-14
Lead Sponsor
Federal University of Rio Grande do Sul
Target Recruit Count
68
Registration Number
NCT02901249

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated
Conditions
Bipolar Disorder
First Posted Date
2016-09-08
Last Posted Date
2024-03-12
Lead Sponsor
University of New Mexico
Target Recruit Count
1037352
Registration Number
NCT02893371
Locations
🇺🇸

Christophe G Lambert, Albuquerque, New Mexico, United States

Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML

Phase 1
Completed
Conditions
Acute Myeloid Leukemia
Interventions
Procedure: allogeneic stem cell transplantation
First Posted Date
2016-09-07
Last Posted Date
2023-04-12
Lead Sponsor
Columbia University
Target Recruit Count
6
Registration Number
NCT02891278
Locations
🇺🇸

Johns Hopkins University Medical Center, Baltimore, Maryland, United States

🇺🇸

Columbia University, New York, New York, United States

Safety of Anti-Depressant for Chronic Obstructive Pulmonary Disease (SAD-COPD)

Not Applicable
Terminated
Conditions
COPD
Anxiety
Depression
Stress
Interstitial Lung Disease
Interventions
Drug: Placebo
First Posted Date
2016-06-27
Last Posted Date
2021-09-10
Lead Sponsor
Duke University
Target Recruit Count
15
Registration Number
NCT02813447
Locations
🇺🇸

Duke Pulmonary Rehabilitation, Durham, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy